RIGL — Rigel Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $30.29
- 30-Day Move
- -28.7%
- Market Cap
- $486M
- Shares Outstanding
- 18,470,000
- P/E Ratio
- 1.34
- P/B Ratio
- 1.99
Rigel Pharmaceuticals Inc
A read-only Alphactor snapshot forRigel Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$30.29
30-Day Move
-28.7%
Market Cap
$486M
Shares Outstanding
18,470,000
P/E Ratio
1.34
P/B Ratio
1.99
$30.29
-28.7%last 90 delayed daily bars
90D High
$49.10
90D Low
$24.95
Avg Volume
401,505
Gross margin is running at 93.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 124.7%, useful for comparing RIGL against peers in Biotechnology.
RIGL is down 28.7% over the last 30 trading days shown on this page.
Latest operating income is $23M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$124.88
Rule of 40
89.9%
Latest Close
$30.29
30-Day Move
-28.7%
Market Cap
$486M
Shares Outstanding
18,470,000
P/E Ratio
1.34
P/B Ratio
1.99
ROE
93.8%
ROA
71.5%
Gross Margin
93.3%
Operating Margin
42.6%
Net Margin
124.7%
Debt / Equity
0.13
Current Ratio
2.42
Latest Revenue
$70M
Revenue
$70M
Gross Profit
$64M
Operating Income
$23M
Net Income
$268M
Gross Margin
9333.0%
Net Margin
12472.0%
Current Ratio
2.42
Debt / Equity
0.13
Fair Value
$124.88
Upside / Downside
+312.3%
Signal
Undervalued
Implied Growth
-6.8%
DCF
$170.78
EV/Rev
$78.98
Growth Assumption
34.8%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$76M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
1.31
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
0.21x
Rule of 40
89.9%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $120M | $-54M | $-59M | $-74M |
| 2023-12-31 | $117M | $-20M | $-25M | $-21M |
| 2024-12-31 | $179M | $24M | $17M | $31M |
| 2025-12-31 | $294M | $125M | $367M | $76M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2026-01-29
$44M
-0.5%
Goldman Sachs
Filed 2026-02-10
$29M
-8.8%
Marshall Wace
Filed 2026-02-13
$26M
--
Renaissance Technologies
Filed 2026-02-12
$23M
+13.7%
BlackRock
Filed 2024-05-10
$22M
--
Geode Capital Management
Filed 2026-02-09
$18M
+0.1%
D.E. Shaw
Filed 2026-02-17
$18M
+38.4%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.